Alison H. Araten, Rachel S. Brooks, Sarah D. W. Choi, Laura L. Esguerra, Diana Savchyn, Emily J. Wu, Gabrielle Leon, Katherine J. Sniezek, Mark P. Brynildsen
{"title":"头孢菌素的耐药性、耐受性和改善其活性的方法","authors":"Alison H. Araten, Rachel S. Brooks, Sarah D. W. Choi, Laura L. Esguerra, Diana Savchyn, Emily J. Wu, Gabrielle Leon, Katherine J. Sniezek, Mark P. Brynildsen","doi":"10.1038/s41429-023-00687-y","DOIUrl":null,"url":null,"abstract":"<p>Cephalosporins comprise a β-lactam antibiotic class whose first members were discovered in 1945 from the fungus <i>Cephalosporium acremonium</i>. Their clinical use for Gram-negative bacterial infections is widespread due to their ability to traverse outer membranes through porins to gain access to the periplasm and disrupt peptidoglycan synthesis. More recent members of the cephalosporin class are administered as last resort treatments for complicated urinary tract infections, MRSA, and other multi-drug resistant pathogens, such as <i>Neisseria gonorrhoeae</i>. Unfortunately, there has been a global increase in cephalosporin-resistant strains, heteroresistance to this drug class has been a topic of increasing concern, and tolerance and persistence are recognized as potential causes of cephalosporin treatment failure. In this review, we summarize the cephalosporin antibiotic class from discovery to their mechanisms of action, and discuss the causes of cephalosporin treatment failure, which include resistance, tolerance, and phenomena when those qualities are exhibited by only small subpopulations of bacterial cultures (heteroresistance and persistence). Further, we discuss how recent efforts with cephalosporin conjugates and combination treatments aim to reinvigorate this antibiotic class.</p>","PeriodicalId":501839,"journal":{"name":"The Journal of Antibiotics","volume":"79 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Cephalosporin resistance, tolerance, and approaches to improve their activities\",\"authors\":\"Alison H. Araten, Rachel S. Brooks, Sarah D. W. Choi, Laura L. Esguerra, Diana Savchyn, Emily J. Wu, Gabrielle Leon, Katherine J. Sniezek, Mark P. Brynildsen\",\"doi\":\"10.1038/s41429-023-00687-y\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Cephalosporins comprise a β-lactam antibiotic class whose first members were discovered in 1945 from the fungus <i>Cephalosporium acremonium</i>. Their clinical use for Gram-negative bacterial infections is widespread due to their ability to traverse outer membranes through porins to gain access to the periplasm and disrupt peptidoglycan synthesis. More recent members of the cephalosporin class are administered as last resort treatments for complicated urinary tract infections, MRSA, and other multi-drug resistant pathogens, such as <i>Neisseria gonorrhoeae</i>. Unfortunately, there has been a global increase in cephalosporin-resistant strains, heteroresistance to this drug class has been a topic of increasing concern, and tolerance and persistence are recognized as potential causes of cephalosporin treatment failure. In this review, we summarize the cephalosporin antibiotic class from discovery to their mechanisms of action, and discuss the causes of cephalosporin treatment failure, which include resistance, tolerance, and phenomena when those qualities are exhibited by only small subpopulations of bacterial cultures (heteroresistance and persistence). Further, we discuss how recent efforts with cephalosporin conjugates and combination treatments aim to reinvigorate this antibiotic class.</p>\",\"PeriodicalId\":501839,\"journal\":{\"name\":\"The Journal of Antibiotics\",\"volume\":\"79 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-12-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Journal of Antibiotics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1038/s41429-023-00687-y\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Antibiotics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1038/s41429-023-00687-y","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Cephalosporin resistance, tolerance, and approaches to improve their activities
Cephalosporins comprise a β-lactam antibiotic class whose first members were discovered in 1945 from the fungus Cephalosporium acremonium. Their clinical use for Gram-negative bacterial infections is widespread due to their ability to traverse outer membranes through porins to gain access to the periplasm and disrupt peptidoglycan synthesis. More recent members of the cephalosporin class are administered as last resort treatments for complicated urinary tract infections, MRSA, and other multi-drug resistant pathogens, such as Neisseria gonorrhoeae. Unfortunately, there has been a global increase in cephalosporin-resistant strains, heteroresistance to this drug class has been a topic of increasing concern, and tolerance and persistence are recognized as potential causes of cephalosporin treatment failure. In this review, we summarize the cephalosporin antibiotic class from discovery to their mechanisms of action, and discuss the causes of cephalosporin treatment failure, which include resistance, tolerance, and phenomena when those qualities are exhibited by only small subpopulations of bacterial cultures (heteroresistance and persistence). Further, we discuss how recent efforts with cephalosporin conjugates and combination treatments aim to reinvigorate this antibiotic class.